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Simple Summary: Tumor suppressing effect of metformin has been reported, and one of mechanism of
this effect is suppression of cancer stem cells (CSCs). However, detailed mechanism of metformin-induced
CSC-inhibitory effect has not been known. We demonstrated that the CSC-suppressive effect of metformin
was associated with AMPK activation/mTOR inhibition and repression of protein prenylation through
suppression of mevalonate pathway in colorectal cancer. Further studies would be needed to investigate
cross-reactions with other mechanisms of the antitumor effect of metformin, and clinical impact of
metformin should be considered as chemopreventive or adjunctive treatment for colorectal tumor.
Abstract: Metformin is a well-known AMPK (AMP-activated protein kinase) activator that suppresses
cancer stem cells (CSCs) in some cancers. However, the mechanisms of the CSC-suppressing effects
of metformin are not yet well understood. In this study, we investigated the CSC-suppressive effect
of metformin via the mevalonate (MVA) pathway in colorectal cancer (CRC). Two colorectal cancer
cell lines, HT29 and DLD-1 cells, were treated with metformin, mevalonate, or a combination of the
two. We measured CSC populations by flow cytometric analysis (CD44+/CD133+) and by tumor
spheroid growth. The expression of p-AMPK, mTORC1 (pS6), and key enzymes (HMGCR, FDPS,
GGPS1, and SQLE) of the MVA pathway was also analyzed. We investigated the effects of metformin
and/or mevalonate in xenograft mice using HT29 cells; immunohistochemical staining for CSC
markers and key enzymes of the MVA pathway in tumor xenografts was performed. In both
HT29 and DLD-1 cells, the CSC population was significantly decreased following treatment with
metformin, AMPK activator (AICAR), HMG-CoA reductase inhibitor (simvastatin), or mTOR
inhibitor (rapamycin), and was increased by mevalonate. The CSC-suppressing effect of these
drugs was attenuated by mevalonate. The results of tumor spheroid growth matched those of the
CSC population experiments. Metformin treatment increased p-AMPK and decreased mTOR (pS6)
expression; these effects were reversed by addition of mevalonate. The expression of key MVA pathway
enzymes was significantly increased in tumor spheroid culture, and by addition of mevalonate,
and decreased upon treatment with metformin, AICAR, or rapamycin. In xenograft experiments,
tumor growth and CSC populations were significantly reduced by metformin, and this inhibitory
effect of metformin was abrogated by combined treatment with mevalonate. Furthermore, in the
MVA pathway, CSC populations were reduced by inhibition of protein prenylation with a farnesyl
transferase inhibitor (FTI-277) or a geranylgeranyl transferase inhibitor (GGTI-298), but not by
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inhibition of cholesterol synthesis with a squalene synthase inhibitor (YM-53601). In conclusion,
the CSC-suppressive effect of metformin was associated with AMPK activation and repression of
protein prenylation through MVA pathway suppression in colorectal cancer.
Keywords: cancer stem cells; metformin; mevalonate pathway; protein prenylation; colorectal cancer
1. Introduction
Colorectal cancer (CRC) is the third most common cause of cancer-related deaths worldwide [1].
Approximately 25% of CRC patients are already stage IV at diagnosis, and a significant proportion of
advanced CRC patients develop resistance to treatment and experience recurrence and metastasis [2].
Therefore, to develop more effective drugs for advanced CRC, we need to target the critical cells and
signaling pathways involved in tumor progression, recurrence, and metastasis.
Cancer stem cells (CSCs) are a main target for decreasing cancer risk, recurrence, and metastasis
and for overcoming resistance to chemotherapy. CSCs are maintained as a subpopulation within
the neoplasm that perpetuates clonal expansion. This subpopulation generally has resistance to
conventional chemotherapy, leading to relapse and metastasis. Therefore, many researchers have
worked to identify critical pathways for maintenance of CSCs and to devise CSC-targeted or
CSC-differentiating therapy [3,4].
Metformin (N′, N′-dimethylbiguanide) is a well-known oral antidiabetic drug that activates
AMP-dependent protein kinase (AMPK). In clinical studies, metformin decreases colon polyp
development, as well as the risk, recurrence, and mortality of CRC [5].
These beneficial effects of metformin are related to AMPK activation, mammalian target of
rapamycin (mTOR) inhibition, cell cycle regulation, and CSC suppression [6–9].
Recent studies reported additional potent effects of metformin on lipid and cholesterol biosynthesis in
colorectal cancer cells. Metformin inhibits transcriptional activation of β-hydroxy-β-methylglutaryl-CoA
(HMG-CoA) reductase, as well as key mediators in the cholesterol biosynthesis pathway [10–12].
The cholesterol biosynthesis/mevalonate pathway, also known as the HMG-CoA reductase pathway,
is critical for cancer cell survival [13]. In clinical studies, elevated cholesterol is strongly associated with high
cancer risk, worse outcomes, and resistance to chemotherapy [14,15], and statin, a cholesterol-lowering
agent and inhibitor of HMG-CoA reductase, decreases cancer risk and has antitumor effects [16].
The mevalonate (MVA) pathway leads to the synthesis of sterols and protein prenylation
that have important roles in tumor growth. Multiple enzymes of this pathway are essential for
proliferation and survival of various types of cancer cells, and are upregulated in many cancers [15,17].
In addition, key final enzymes of the MVA pathway, including farnesyl diphosphate synthase (FDPS),
geranylgeranyl pyrophosphate synthase 1 (GGPS1), and squalene epoxidase (SQLE), have been linked
to activation of farnesylated and geranylgeranylated proteins, such as Ras and Ral/Rho, and cholesterol
synthesis, respectively.
However, there are no data that elucidate the direct relationship between metformin-induced
suppression of CSCs and its detailed mechanism in the MVA pathway. Here, we showed that CSC
suppression by metformin is associated with inhibition of protein prenylation, rather than cholesterol
synthesis, through the MVA pathway.
2. Results
2.1. Metformin, an AMPK Activator and mTOR Inhibitor, Suppresses Cancer Stem Cells
Based on our previously reported data [8], we selected HT29 and DLD-1 cells from the available
metformin-sensitive CRC cell lines. We confirmed decreased mRNA expression of the CSC markers
Lgr5, CD44, and CD133 (Figure 1A).
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Figure 1. Suppression of cancer stem cells by metformin, statin, AMPK activator, and mTOR inhibitor. 
(A) After 48 h of treatment with metformin (10 mM), mRNA levels of CSC markers in HT29 and DLD-
1 cells were analyzed by qPCR. (B) Heatmap analysis representing transcripts of CSC markers using 
public RNA-sequencing data of LoVo cells treated with and without metformin for 8 h and 24 h 
(GSE76342). (C) Western blot analysis of p-AMPK and p-S6 expression levels in HT29 and DLD-1 cells 
after 48 h of treatment with control vehicle, metformin (10 mM), mevalonate (1 mM), or combination 
(metformin (10 mM) and mevalonate (1 mM)). (D) HT29 and DLD-1 cells were treated with metformin 
(10 mM), simvastatin (2 μM), AICAR (1 mM), or rapamycin (200 nM). After 48 h, the proportions of 
CD44+/CD133+ cells were analyzed by flow cytometry using anti-CD44-FITC and anti-CD133-PE. (E, 
F) In tumor sphere cultures treated with metformin (10 mM), simvastatin (2 μM), AICAR (1 mM), or 
rapamycin (200 nM) for 7 days, the number of tumor spheres (≥200 µm in diameter) was counted and 
compared to the counts in control cultures. Data are expressed as the mean ± standard error of three 
independent experiments; * p < 0.05, ** p < 0.01, and *** p < 0.001 (compared with control). 
In addition, in another public transcript data set (GSE76342) for the colon cancer cell line LoVo 
with or without metformin treatment, we found that metformin inhibited expression of the CSC 
markers Lgr5, ASCL2, EPHB3, OLFM4, BMI1, Lrig1, TERT, CD44, and CD133 (Figure 1B). Because 
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(A) fter 48 h of treatment ith etfor in (10 mM), mRNA levels of CSC markers in HT29 and
DLD-1 cells were analyzed by qPCR. (B) Heatmap analysis representing transcripts of CSC markers
using public RNA-sequencing data of LoVo cells treated with and without metformin for 8 h and 24 h
(GSE76342). (C) Western blot analysis of p-AMPK and p-S6 expression levels in HT29 and DLD-1 cells
after 48 h of treatment with control vehicle, metformin (10 mM), mevalonate (1 mM), or combination
(metformin (10 mM) and mevalonate (1 mM)). (D) HT29 and DLD-1 cells were treated with metformin
(10 mM), simvastatin (2 µM), AICAR (1 mM), or rapamycin (200 nM). After 48 h, the proportions of
CD44+/CD133+ cells were analyzed by flow cytometry using anti-CD44-FITC and anti-CD133-PE.
(E,F) In tumor sphere cultures treated with metformin (10 mM), simvastatin (2 µM), AICAR (1 mM),
or rapamycin (200 nM) for 7 days, the number of tumor spheres (≥200 µm in diameter) was counted
and compared to the counts in control cultures. Data are expressed as the mean ± standard error of
three independent experiments; * p < 0.05, ** p < 0.01, and *** p < 0.001 (compared with control).
In addition, in another public transcript data set (GSE76342) for the colon cancer cell line
LoVo with or without metformin treatment, we found that metformin inhibited expression of the
CSC markers Lgr5, ASCL2, EPHB3, OLFM4, BMI1, Lrig1, TERT, CD44, and CD133 (Figure 1B).
Because one of the well-known pathways of metformin action is the AMPK-dependent mTOR pathway,
we examined the expression of activated AMPK and mTOR signaling molecules after treatment with
metformin. Metformin treatment increased p-AMPK and decreased p-S6 expression (Figure 1C).
Using flow cytometric analysis, we confirmed that the CSC population was significantly decreased by
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metformin, AICAR (AMPK activator), simvastatin (HMG-CoA reductase inhibitor), and rapamycin
(mTOR inhibitor) (Figure 1D). In addition, in tumor sphere culture experiments, tumor sphere formation
was significantly decreased by treatment with these drugs (Figure 1E,F).
2.2. Metformin Suppresses Key Enzymes of the Mevalonate Pathway
Some reports have shown potent effects of metformin on lipid and cholesterol biosynthesis in cancer
cells [11,12]. Therefore, we postulated that metformin may inhibit HMG-CoA reductase (HMGCR),
as well as several important enzymes of the MVA pathway, in CRC. In the same data set shown in
Figure 1B, we found that metformin reduced key enzymes of the MVA pathway, including HMGCR,
mevalonate kinase (MVK), phospho-mevalonate kinase (PMVK), mevalonate decarboxylase (MVD),
FDPS, GGPS, and SQLE (Figure 2A).
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Figure 2. Regulation of enzymes of the mevalonate pathway and cancer stem cell population by 
metformin, AMPK activator, mTOR inhibitor, and mevalonate. (A) Heatmap analysis representing 
transcripts of enzymes of the MVA pathway using the same public RNA-sequencing data set as in 
Figure 1B. (B) Western blot analysis for the expression of FDPS and GGPS1 was performed after 5 
days of 2D adherent culture and 3D tumor sphere culture and after 5 days’ treatment with metformin 
(10 mM). (C) mRNA levels of HMGCR, FDPS, GGPS1, and SQLE were measured by qPCR under the 
same conditions as in (B). (D) HT29 and DLD-1 tumor spheres were treated with metformin (10 mM), 
simvastatin (2 μM), AICAR (1 mM), rapamycin (200 nM), or mevalonate (1 mM) for 7 days and then 
subjected to qPCR analysis of HMGCR, FDPS, GGPS1, and SQLE. (E) HT29 and DLD-1 cells were 
treated with metformin (10 mM), simvastatin (2 μM), AICAR (1 mM), rapamycin (200 nM), 
mevalonate (1 mM), or a combination of each drug with mevalonate (1 mM) for 48 h. Cells were 
subjected to flow cytometry to analyze CD44+/CD133+ cells using anti-CD44-FITC and anti-CD133-
PE. (F) In tumor sphere cultures with metformin (5 mM), mevalonate (1 mM), or a combination of 
metformin (5 mM) and mevalonate (1 mM) for 7 days, the number of tumor spheres (≥200 µm in 
diameter) was counted and compared to the counts in control cultures. Magnification, 40×. Data are 
expressed as the mean ± standard error of three independent experiments; * p < 0.05, ** p < 0.01, and 
*** p < 0.001 (compared with control). 
To demonstrate increased activity of the MVA pathway in CSCs of CRC, we cultured tumor 
spheres and found significantly elevated protein and mRNA levels of key enzymes of the MVA 
pathway, including HMGCR, FDPS, GGPS1, and SQLE, in tumor spheroids compared to 2D adherent 
cultured cells (Figure 2B,C). These findings suggest that the MVA pathway may have an important 
role in CRC tumorigenesis by promoting CSCs of CRC. In addition, metformin significantly reduced 
expression of key enzymes of the MVA pathway that were upregulated in 3D tumor spheroid 
cultures of CRC cells (Figure 2B,C). 
We asked whether other AMPK/mTOR regulators can inhibit enzymes of the MVA pathway. 
Thus, we confirmed significant decreases in mRNA levels of these key enzymes of the MVA pathway 
in tumor spheres after 7 days of treatment with metformin, AICAR, or rapamycin. We also tested 
simvastatin on tumor spheres of CRC cells, and found that reduction of these key enzymes of the 
MVA pathway by simvastatin was relatively weak and inconsistent compared to the effects of 
metformin (Figure 2D). Moreover, treatment with mevalonate promoted expression of these key 
enzymes of the MVA pathway (Figure 2D), resulting in an increased proportion of CSCs among CRC 
cells (Figure 2E). In addition, mevalonate treatment attenuated the suppressive effect of metformin 
on CSCs of CRC and the formation of tumor spheroids (Figure 2E,F). This reversal effect of 
mevalonate was also observed in treatment with AICAR, simvastatin, and rapamycin in both cell 
lines (Figure 2E). 
Taken together, these results demonstrate that the MVA pathway was activated in CSCs and 
that metformin, AMPK activation, and mTOR inhibition suppressed CSCs through inhibiting the 
expression of key enzymes of the MVA pathway. 
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of the MVA pathway using the same public RNA-sequencing data set as in Figure 1B. (B) Western blot
analysis for the expression of FDPS and GGPS1 was performed after 5 days of 2D adherent culture
and 3D tumor sphere culture and after 5 days’ treatment with metformin (10 mM). (C) mRNA levels of
HMGCR, FDPS, GGPS1, and SQLE were measured by qPCR under the same conditions as in (B). (D) HT29
and DLD-1 tumor spheres were treated with metformin (10 mM), simv statin (2 µM), AICAR (1 mM),
rapamycin (200 nM), or mevalonate (1 mM) for 7 days and then subjected to qPCR analysis of HMGCR,
FDPS, GGPS1, and SQLE. (E) HT29 and DLD-1 cells were treated with metformin (10 mM), simvastatin
(2 µM), AICAR (1 mM), rapamycin (200 nM), mevalonate (1 mM), or a combination of each drug with
mevalonate (1 mM) for 48 h. Cells were subjected to flow cytometry t analyze CD44+/CD133+ cells using
anti-CD44-FITC and anti-CD133-PE. (F) In tumor sphere cultures with metformin (5 mM), mevalonate
(1 mM), or a co bination of metformin (5 mM) and mevalonate (1 mM) for 7 days, the nu ber of tumor
spheres (≥200 µm in diameter) was counted and compared to the counts in control cultures. Magnification,
40×. Data are expressed as the mean ± standard error of three independent experiments; * p < 0.05,
** p < 0.01, and *** p < 0.001 (compared with control).
To demonstrate increased activity of the MVA pathway in CSCs of CRC, we cultured tumor spheres
and found significantly elevated protein and mRNA levels of key enzymes of the MVA pathway, including
HMGCR, FDPS, GGPS1, and SQLE, in tumor spheroids compared to 2D adherent cultured cells (Figure 2B,C).
These findings suggest that the MVA pathway may have an important role in CRC tumorigenesis by
promoting CSCs of CRC. In addition, metformin significantly reduced expression of key enzymes of the
MVA pathway that were upregulated in 3D tumor spheroid cultures of CRC cells (Figure 2B,C).
We asked whether other AMPK/mTOR regulators can inhibit enzymes of the MVA pathway.
Thus, we confirmed significant decreases in mRNA levels of these key enzymes of the MVA pathway
in tumor spheres after 7 days of treatment with metformin, AICAR, or rapamycin. We also tested
simvastatin on tumor spheres of CRC cells, and found that reduction of these key enzymes of the MVA
pathway by simvastatin was relatively weak and inconsistent compared to the effects of metformin
(Figure 2D). Moreover, treatment with mevalonate promoted expression of these key enzymes of the
MVA pathway (Figure 2D), resulting in an increased proportion of CSCs among CRC cells (Figure 2E).
In addition, mevalonate treatment attenuated the suppressive effect of metformin on CSCs of CRC and
the formation of tumor spheroids (Figure 2E,F). This reversal effect of mevalonate was also observed in
treatment with AICAR, simvastatin, and rapamycin in both cell lines (Figure 2E).
Taken together, these results demonstrate that the MVA pathway was activated in CSCs and
that metformin, AMPK activation, and mTOR inhibition suppressed CSCs through inhibiting the
expression of key enzymes of the MVA pathway.
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2.3. Metformin Reduced CSCs through Inhibition of Protein Prenylation, rather than Cholesterol Synthesis,
in the MVA Pathway
We further investigated the specific final processes of the MVA pathway associated with
metformin-induced suppression of CSCs by performing experiments using inhibitors of protein prenylation,
such as farnesylation and geranylgeranylation, and of cholesterol synthesis. We used the farnesyl
transferase inhibitor FTI-277, the geranylgeranyl transferase inhibitor GGTI-298, and the squalene
synthase inhibitor YM-53601. To evaluate the CSC-specific effects and exclude the possibility of direct
cellular toxicity of these inhibitors, we selected concentrations of inhibitors showing CSC-suppressive
effects without significant cell death. For example, higher concentrations of YM-53601 (>10 µM) induced
significant cell death without changes in CSC population (data not shown). FTI-277 and GGTI-298
induced suppression of the CSC population in a dose-dependent manner, similar to metformin treatment
(Figure 3A). Moreover, combined treatment of FTI-277 and GGTI-298 decreased the CSC population
even further (Figure 3A). However, YM-53601 did not show a significant effect on CSC populations
(Figure 3A). Furthermore, in tumor sphere formation assays (Figure 3B,C), treatment with FTI-277,
GGTI-298, or YM-53601 produced results similar to those observed in flow cytometric analyses of CSC
populations. In addition, to confirm the decrease of protein prenylation by metformin, we performed
Western blot analysis to identify the change of shifted prenylated protein bands of RAS and Ral A by
farnesylation and geranylgeranylation, respectively. Although the shifted bands were weak in some
conditions, we found the decrease of shifted prenylated protein bands of RAS and Ral A (Supplementary
Figure S1). These results demonstrated that metformin may suppress CSCs through inhibition of protein
prenylation, via farnesylation and geranylgeranylation, rather than through cholesterol synthesis by SQLE.
2.4. Tumor-Suppressing Effect of Metformin in a Murine Xenograft Model Was Reversed by Additional
Treatment with Mevalonate
We performed in vivo xenograft experiments to evaluate the effect of mevalonate on
metformin-induced tumor suppression. At 14 days after implantation of HT29 cells, we treated
mice with mevalonate, metformin, or a combination of mevalonate and metformin, by intraperitoneal
injection for 21 days (Figure 4A). In the metformin-treated group, tumor growth was suppressed by 20%
compared to the control group. Treatment with mevalonate alone showed a trend toward further tumor
growth relative to the control group; the addition of mevalonate to metformin treatment induced a
significant increase in tumor growth compared to metformin treatment alone, indicating that mevalonate
could reverse the tumor-suppressing effect of metformin (Figure 4B–D). In immunohistochemical
(IHC) staining for the CSC markers CD44 and CD133, the metformin treatment group showed
significantly decreased IHC scores for CD44 and CD133; combination treatment of metformin and
mevalonate induced significant increases in both CSC markers compared to metformin treatment alone
(Figure 4E,F). Moreover, key enzymes of protein prenylation of the MVA pathway, FDPS and GGPS1,
were suppressed by metformin, and this suppressive effect was reversed by addition of mevalonate
(Figure 4G,H). From these results, we confirmed that mevalonate could reverse the CSC-suppressing
effect of metformin in the in vivo xenograft model, and metformin-induced CSC suppression could be
associated with suppression of key enzymes of the MVA pathway. In addition, we performed Ki67
staining to show antiproliferative effect of metformin, and found a significant decrease of Ki67 staining
by treatment of metformin (Supplementary Figure S2). Therefore, the tumor-suppressing effect of
metformin would not depend on only suppression of CSCs. However, because the CSCs are important
for tumor initiation, persistent progression, and metastasis, and the effect of metformin was more
prominent on CSC population in our previous data [8], we focused on CSC suppression by metformin.
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Figure 3. Cancer stem cell proportion was reduced by inhibition of protein prenylation, but not by
inhibition of squalene synthase in the mevalonate pathway. (A) HT29 and DLD-1 cells were treated
with metformin (5 or 10 mM), farnesyltransferase inhibitor (FTI-277; 20, 30, or 40 µM), geranylgeranyl
transferase I inhibitor (GGTI-298; 5, 10, or 20 µM), or squalene synthase inhibitor (YM-53601; 1, 5,
or 10 µM) for 48 h, and then the CD44+/CD133+ population w s analyzed by flow cytometry using
anti-CD44-FITC and anti-CD133-PE. (B,C) In tumor sphere cultures treated with metformin (10 mM),
FTI-277 (40 µM), GGTI-298 (20 µM), or YM-53601 (10 µM) for 5 days, the number of tumor spheres
(≥200 µm in diameter) was counted and compared to the counts in control cultures. Magnification,
40×. Data are expressed as the mean ± standard error of three independent experiments; * p < 0.05,
** p < 0.01, and *** p < 0.001 (compared with control).
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Figure 4. The tumor-suppressing effect of metformin was reversed by addition of mevalonate in
a mouse xenograft model. (A,B) HT29 cells were injected subcutaneously into both flanks of nude
mice. Implanted mice were randomly and evenly allocated into four groups: vehicle, metformin
(by intraperito eal injection, 250 mg/kg in 200 µL PBS daily), mevalonate (by intraperitoneal injection,
10 mg/kg in 200 µL PBS daily), or th combination of the same daily doses of both metformin and
mevalonate. Tumors were measured, and mice were sacrificed on day 21. In mice implanted with
HT29 cells, tumor growth (C) and tumor weights (D) were compared between the four groups. In (C),
* denotes p < 0.05 for comparison with the combination group. (E) IHC to evaluate expression of CD44
and CD133 was performed on sections of formalin-fixed, paraffin-embedded, dissected xenograft tumor
samples from mice treated with vehicle, metformin alone, mevalonate alone, or metformin combined
with mevalonate. (F) IHC scores for CD44 or CD133-stai ed cells were analyzed using Image J. (G) IHC
was performed for FDPS and GGPS1 and (H) analyzed using Image J. Magnification, 200×. Data are
expressed as the mean ± standard error; n = 10 per group. * p < 0.05, ** p < 0.01, and *** p < 0.001.
3. Discussion
Several previous studies revealed the inhibitory effect of metformin on CSCs [8,9], but the detailed
mechanism has not been well defined. In this study, we identified that metformin serves as a negative
regulator of the MVA pathway and exerts CSC-suppressive effects in CRC through the inhibition
of protein prenylation processes of the MVA pathway. Regarding the relationship among tumor
growth, the cholesterol pathway, and metformin, Sharma at al. showed increased cholesterol levels
and elevated expression of certain cholesterol regulatory genes in malignant breast tumor tissues,
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such as HMGCR, LDLR, and SREBP1 [12]. They also demonstrated that metformin inhibited cholesterol
levels in breast cancer MDA-MB-231 cells, with decreased expression of cholesterol regulatory
genes. In addition, Wahdan-Alaswad et al. suggested that metformin suppressed triple-negative
MDA-MB-231 cells by reducing fatty acid synthesis [10,11]. Furthermore, they showed that metformin
targets the cholesterol biosynthesis pathway and stabilizes GM1 lipid rafts, reducing membrane
EGFR (epidermal growth factor receptor) signaling and its activation in triple-negative breast
cancer. Moreover, they demonstrated that the combination of metformin with the statin-mimetic
methyl-β-cyclodextrin (MβCD) synergistically attenuates cholesterol biosynthesis and cell proliferation.
In particular, they suggested that metformin might act as an HMGCR inhibitor. In our analysis using
their public RNA-seq data for the metformin-treated cell line, we found that expression of most genes
involved in the MVA pathway was reduced by metformin treatment (Figure 2A). Several other studies
also demonstrated that metformin may inhibit HMGCR and SREBP1 in different cell types [18–20].
However, the detailed relationship between metformin-induced regulation of the MVA/cholesterol
pathway and CSCs has not been defined.
Our study aimed to investigate how metformin affects the MVA pathway and whether this may
be related to the inhibitory effect on CSCs. We showed that metformin inhibited CSCs in CRC cells,
with concomitant decreases in MVA pathway enzymes, including HMGCR, FDPS, GGPS1, and SQLE.
We observed that the inhibitory effect of metformin on CSCs and MVA pathway enzymes was reversed
by addition of mevalonate. The elevated expression of these MVA pathway enzymes was related to
increased CSCs of CRC, suggesting a close relationship between CSCs and activated MVA pathway.
Interestingly, we demonstrated that CSCs could be reduced through the inhibition of protein
prenylation, but not by inhibition of cholesterol synthesis. The prenylation of Ras and Ral/Rho proteins
via MVA pathway-dependent farnesylation and geranylgeranylation, respectively, is important for
their function. The Ras, Ral, and Rho families are associated with many tumor characteristics, such as
invasive growth, cell survival, and three-dimensional growth, [21,22], and play critical roles in tumor
development, progression, and metastasis, including activation of CSCs [23–25]. Therefore, inhibition
of protein prenylation via the MVA pathway might be an important target for CSC suppression.
In addition, Freed-Pastor and Mizuno et al. reported that mutant p53 upregulated expression of MVA
pathway enzymes [17]. The tumor characteristics of metabolic subtypes of CRC, such as consensus
molecular subtype 3 or KRAS mutations, may also be related to MVA pathway activation.
Metformin is a well-known AMPK activator, and activation of AMPK inhibits mTOR signaling
and energy-consuming pathways [26,27]. Ching and Abraham et al. reported that activation of
AMPK inhibits acetyl-CoA carboxylase (ACC) activity, which is related to fatty acid synthesis [28].
Many studies have reported that metformin induces anticancer activity by AMPK activation and mTOR
inhibition. Thus, we also investigated the relationship between AMPK/mTOR regulators and the MVA
pathway, and confirmed that an AMPK activator and an mTOR inhibitor reduced CSC populations;
these effects were reversed by adding mevalonate. Moreover, the AMPK activator and mTOR inhibitor
decreased the expression of mediator enzymes of the MVA pathway, suggesting regulation of this
pathway by AMPK/mTOR signaling. In addition, we found that metformin-resistant cells (SW620) did
not show significant change of AMPK/mTOR signals and reduction of key enzymes expression of the
MVA pathway by treatment of metformin (Supplementary Figure S3).
Statin is a drug that lowers cholesterol through HMGCR inhibition and can decrease cancer
risk [29]. We also showed that statin was a potent inhibitor of HMGCR and had a CSC-suppressive
effect. However, the inhibitory effects of statin on key enzymes of the MVA pathway were weaker and
less consistent than those of metformin, suggesting the importance of additional effects of metformin
on the MVA pathway via AMPK activation and mTOR inhibition. Based on the mechanism of CSC
suppression by inhibition of protein prenylation, these candidate drugs, such as metformin and
AMPK activators, could be useful for adjunctive treatment in chemotherapy for advanced CRC or in
chemoprevention for high-risk CRC groups if they have a wide margin of safety.
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In summary, we investigated the detailed relationship between metformin-induced suppression
of CSCs and the MVA pathway. Metformin-induced CSC suppression could occur through AMPK
activation and protein prenylation inhibition, rather than through inhibition of cholesterol synthesis
via the MVA pathway (Figure 5). However, because metformin has many molecular mechanisms
of antitumor effect, we could not elucidate the detailed interaction between prenylation-dependent
and other direct and indirect mechanisms of metformin-induced antitumor or CSC suppression.
Further studies would be needed to investigate these cross-reactions among direct and indirect
mechanisms of the CSC-suppressing effect of metformin.
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4. ethods
4.1. Cell Lines and Culture Conditions
HT29 and DLD-1 colorectal cancer cell lines were purchased from the American Type Culture
Collection (Manassas, VA, USA). Cell lines were maintained in Dulbecco modified Eagle’s medium
(DMEM; Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Gibco, Franklin
Lakes, NJ, USA) and 1% penicillin/streptomycin (Invitrogen, Carlsbad, CA, USA) at 37 ◦C in 5% CO2.
4.2. Tumor Sphere Culture Assay
HT29 and DLD-1 cells (2000 or 4000 cells per well) were plated in 24-well ultra-low adhesive
plates (Corning Incorporated, Corning, NY, USA) in sphere formation medium with drugs for
5 or 7 days. The sphere formation medium was serum-free DMEM-F12 supplemented with B27
(Life Technologies, Carlsbad, CA, USA), 20 ng/mL epidermal growth factor, 10 ng/mL basic fibroblast
growth factor (R & D Systems, Minneapolis, MN, USA), 1% penicillin/streptomycin, and 2 mM
L-glutamine (Life Technologies, Carlsbad, CA, USA). Cells were incubated in a 5% CO2 chamber at
37 ◦C, and 500 µL of the culture medium was changed every 48 h. After 5 or 7 days, the number of
tumor spheres was counted under a microscope (Olympus, Tokyo, Japan, BX51 microscope).
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4.3. Microarray Data Analysis Using a Public Data Set
We performed a microarray data analysis of GSE76342 using the limma package in R. Limma is
an R/Bioconductor software package that provides an integrated solution for analyzing data from gene
expression experiments. CEL files have been deposited to the Gene Expression Omnibus database
(http://www.ncbi.nlm.nih.gov/geo) under the accession number GSE76342.
4.4. Flow-Cytometric Analysis and Fluorescence-Activated Cell Sorting (FACS)
HT29 and DLD-1 were plated in 6-well plates at a density of 2 × 105 cells/well and treated
with metformin and other reagents. After 48 h, the prepared cells were detached with Accutase
(Millipore, Billerica, MA, USA) and resuspended in FACS buffer (1 × PBS, 1% bovine serum albumin,
and 2 mM ethylenediaminetetraacetic acid). Primary antibodies against CSC markers (PE-conjugated
anti-CD133 and FITC-conjugated anti-CD44) were added. Specific information of antibodies used in the
study was given in Supplementary Table S2. Samples were incubated for 10 min at 4 ◦C, washed with
FACS buffer, and subjected to flow cytometry for analysis using a FACSVerse (BD Biosciences, San Diego,
CA, USA) coupled to a computer with BD FACSuite software.
4.5. RNA Extraction and qPCR
Total RNA was isolated using TRIZOL Reagent (Invitrogen). Equal amounts of cDNA were
synthesized using the reverse transcription 5×Master Pro Mix (ELPISBIO, Daejeon, Korea), and mixed
with 2× SYBR Green with high ROX (ELPISBIO). qPCR reactions were performed using the gene-specific
primers in Supplementary Table S1. All qPCRs performed using SYBR Green were conducted at 55 ◦C
for 10 min, 95 ◦C for 10 min, and 40 cycles of 95 ◦C for 15 s and 60 ◦C for 1 min. The specificity of the
reaction was verified by melt curve analysis.
4.6. Western Blotting
Prepared cells were lysed using a protein extraction solution (iNtRON Biotechnology, Gyeonggi,
Korea). After protein quantification, 20 µg portions of protein extracts were fractionated using 12%
or 15% sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to polyvinylidene
fluoride membranes (Bio-Rad, Hercules, CA, USA). After blocking with 10% skim milk, membranes were
incubated with primary antibodies overnight at 4 ◦C. Subsequently, membranes were incubated with
secondary antibodies for 1 h at room temperature. Proteins were detected using an ECL Western blotting
detection kit (Amersham Biosciences, Freiburg, Germany) and light was captured on Kodak image film.
For Western blotting for prenylated proteins, prepared cells were harvested and lysed in 0.2 mL
of high concentration of salt buffer (50 mM Tris-HCl, pH 7.5/150 or 450 mM NaCl, 0.5% NP-40).
Then, protein lysate was resolved in 12% or 15% SDS/polyacrylamide gel.
4.7. Drugs and Antibodies
Metformin and FTI-277 were purchased from Sigma (St. Louis, MO, USA). AICAR, simvastatin,
GGTI-298, and YM-53601 were purchased from Cell Signaling Technology (Danvers, MA, USA),
Merck Millipore (Darmstadt, Germany), R & D systems (Minneapolis, MN, USA), Cayman (Ann Arbor,
Michigan, AN, USA). Mevalonate, rapamycin were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). The antibodies used for flow cytometry, Western blotting, and IHC analysis included:
anti-AMPK, anti-pAMPK (Thr172), anti-S6, and anti-p-S6 (Ser235/236) (Cell Signaling Technology, Danvers,
MA, SAD), anti-GGPS1 (Santa Cruz Biotechnology, Dallas, TX, USA), anti-FDPS (Abcam, Cambridge,
UK), anti-PROM1 (CD133) (MACS, Bergisch Gladbach, Germany), anti-CD44 (eBioscience, San Diego, CA,
USA), phycoerythrin (PE)-conjugated anti-PROM1 (CD133), and fluorescein (FITC)-conjugated anti-CD44
(MACS). Additional information on antibodies and drugs is shown in Supplementary Tables S2 and S3.
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4.8. In Vivo Mouse Xenograft Experiments
Six-week-old male BALB/c athymic nude mice were purchased from Central Lab (Seoul, Korea)
and acclimated for 1 week. Mouse experiments were performed in accordance with protocols approved
by the Committee on Care and Use of Laboratory Animals of Yonsei University College of Medicine
(Seoul, Korea) and according to institutional guidelines and policies.
HT29 cells were suspended in Matrigel (BD Bioscience) at a density of 1 × 106 cells/200 µL, diluted
1:1 in PBS, and subcutaneously injected into both flanks of the mice. After 2 weeks, the implanted mice
were randomly divided into four groups (5 mice per group): control, metformin only, mevalonate
only, and combination (metformin and mevalonate). All drugs were injected intraperitoneally
(metformin: 250 mg/kg in 200 µL PBS; mevalonate: 10 mg/kg in 200 µL PBS) on a daily basis
for 21 days. Vehicle control (200 µL of PBS) was injected intraperitoneally into the mice in the control,
metformin-only, and mevalonate-only groups. Tumor sizes were measured each day using calipers,
and tumor volumes were calculated based on the following formula: tumor volume = length × (width)2
/ 2. All mice were sacrificed 21 days after the first drug treatment and the tumor masses were dissected.
The dissected tumors were placed in 4% paraformaldehyde (PFA) for immunohistochemistry (IHC)
and were collected for further analysis.
4.9. Immunohistochemistry
IHC for CD133, CD44, GGPS1, and FDPS was performed on 4 µm sections of formalin-fixed,
paraffin-embedded, dissected tumor samples. The paraffin-embedded sections were deparaffinized
in xylene and rehydrated in gradually decreasing concentrations of ethanol. Antigen retrieval
was performed using sodium citrate buffer (10 mM, pH 6.0) in a heated pressure cooker for
5 or 7 min. After incubation with 3% hydrogen peroxide for 30 min to block endogenous
peroxidase activity, sections were incubated in a blocking reagent for 30 min at room temperature.
Sections were incubated with primary antibodies overnight at 4 ◦C, followed by secondary
antibody for 30 min at room temperature. After slides were developed with a Vectastain ABC
kit (Vector Laboratories, Burlingame, CA, USA), immunodetection was performed using DAB solution
(Dako, Carpinteria, CA, USA). After counterstaining with hematoxylin, IHC staining was evaluated by
light microscopy and immunoactivity was assessed based on the proportion of immunostained tumor
cells. Additional information on antibodies is shown in Supplementary Table S2.
We measured the intensity of CSC markers (CD44 and CD133) and IHC scores using IHC profiles
based on the Image J program [30]. The IHC score calculation was score = (number of pixels in a zone
× score of the zone)/total number of pixels in the image. The score of the zone was assigned as 4 for
high positive zones, 3 for positive zones, 2 for low positive zones, and 1 for negative zones.
4.10. Statistical Analysis
Statistical analyses were performed using IBM SPSS Statistics version 20.0 (IBM Co., Armonk,
NY, USA). For the evaluation of two data sets, unpaired Student’s t tests or Mann–Whitney tests were
performed. To evaluate more than two groups, one-way or two-way analysis of variance was applied.
Every experiment was conducted at least in triplicate to ensure reliability. All calculated p-values were
two-sided and p < 0.05 was considered statistically significant.
5. Conclusions
We investigated mechanism of metformin-induced CSC-inhibitory effect in the field of tumor
metabolism, and demonstrated that the CSC-suppressive effect of metformin was associated with
AMPK activation/mTOR inhibition and repression of protein prenylation through suppression of
mevalonate pathway in colorectal cancer. In the future, clinical usefulness of metformin might be
considered as chemopreventive or adjunctive treatment for colorectal tumor.
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